Lysosomes Integrate Metabolic-Inflammatory Cross-talk in Primary Macrophage Inflammasome Activation*

Kassandra Weber and Joel D. Schilling

From the Diabetic Cardiovascular Disease Center, the Department of Medicine, and the Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, 63110

Background: Although macrophage inflammasome activation has been implicated in metabolic diseases, its regulation is not well understood.

Results: Palmitate and LPS trigger IL-1β release via lysosome- and calcineurin-mediated pathways.

Conclusion: The lysosome is a key regulator of signal 1 and signal 2 in lipotoxic inflammasome activation.

Significance: Molecular pathways involved in lipid-induced inflammasome activation may be useful targets for obesity- and diabetes-related disorders.

Macrophage dysfunction and inflammasome activation have been implicated in the pathogenesis of diabetes and its complications. Prolonged inflammation and impaired healing are hallmarks of the diabetic response to tissue injury, and excessive inflammasome activation has been associated in these phenotypes. However, the mechanisms that regulate the inflammasome in response to lipid metabolic and inflammatory stress are incompletely understood. We have shown previously that IL-1β secretion is induced in primary macrophages exposed to the dietary saturated fatty acid palmitate in combination with LPS. In this study, we sought to unravel the mechanisms underlying the activation of this lipotoxic inflammasome. We demonstrate that palmitate-loaded primary macrophages challenged with LPS activate the NLRP3 inflammasome through a mechanism that involves the lysosome. Interestingly, the lysosome was involved in both the regulation of pro-IL-1β levels and its subsequent cleavage/release. The lysosomal protease cathepsin B was required for IL-1β release but not pro-IL-1β production. In contrast, disrupting lysosomal calcium regulation decreased IL-1β release by reducing pro-IL-1β levels. The calcium pathway involved the calcium-activated phosphatase calcineurin, which stabilized IL-1β mRNA. Our findings provide evidence that the lysosome plays a key role in both the priming and assembly phases of the lipotoxic inflammasome. These findings have potential relevance to the hyperinflammatory phenotypes observed in diabetics during tissue damage or infection and identify lysosomes and calcineurin as potential therapeutic targets.

The prevalence of obesity and diabetes continues to grow at a staggering rate worldwide. Complications of these metabolic diseases account for significant morbidity, mortality, and health care costs. Evidence is accumulating that macrophage dysfunction in diabetes may contribute to several clinically important sequelae including impaired wound healing, excessive atherosclerosis, adverse cardiac remodeling after myocardial infarction, and increased susceptibility to infection (1–5). However, the mechanisms underlying these inflammatory defects in macrophages are not well understood.

The metabolic perturbations of diabetes likely play a key role in immune cell dysfunction in this disease. In addition to hyperglycemia, diabetes is characterized by substantial lipid metabolic abnormalities including excessive triglyceride and fatty acid levels in circulation and non-adipose tissues. Long chain saturated fatty acids (SFAs)2 such as palmitate are enriched in states of nutrient excess and are thought to be particularly pathogenic in diabetic patients. Consistent with this, the exposure of cells to elevated concentrations of SFAs can produce insulin resistance, ER stress, oxidative stress, and cell death, a phenomenon referred to as lipotoxicity (6). Consequently, there is significant interest in understanding how lipids modulate macrophage inflammatory and reparative functions in diabetes. Our previous studies have shown that lipid-loaded macrophages exposed to inflammatory stimuli such as LPS undergo a cell death response that occurs via a TRIF-dependent pathway involving lysosome dysfunction (1). In addition, we have demonstrated increased ceramide biosynthesis in lipid-stressed primary macrophages, which augments the release of important pro-inflammatory cytokines such as IL-1β (2).

The processing and release of IL-1β from macrophages is regulated by a multiprotein complex known as the inflammasome (7). Recently, the inflammasome has gained attention as a contributor to several important cardiometabolic diseases including atherosclerosis, post-myocardial infarction remodeling, and diabetes (8–11). Activation of the inflammasome is a multistep process that requires a priming signal to induce the expression of IL-1β (signal 1) and a second “stress” signal to

* This work was supported, in whole or in part, by National Institutes of Health Grant K08HL098373 (to J. D. S.).

1 To whom correspondence should be addressed: Diabetic Cardiovascular Disease Ctr., Washington University School of Medicine, St. Louis, MO 63110. E-mail address: jschilli@dom.wustl.edu.

2 The abbreviations used are: SFA, saturated fatty acid; ER, endoplasmic reticulum; ROS, reactive oxygen species; BHA, butylated hydroxyanisole; BHT, butylated hydroxytoluene; pMAC, peritoneal macrophage; qRT-PCR, quantitative RT-PCR; LDH, lactate dehydrogenase; Z-, benzyloxycarbonyl-; BAF, baflomycin A; 2-APB, 2-aminoethoxydiphenyl borate; CSA, cyclosporine; MPTP, mitochondrial permeability transition pore; TRIF, TIR-domain-containing adapter-inducing interferon-β; TLR, Toll-like receptor.
activate cytosolic assembly of the caspase-1-associated proteolytic complex (signal 2) (12). The inflammasome components include the adaptor protein apoptosis-associated speck-like protein containing a caspase activation and recruitment domain, a NOD-like receptor family member (NLRP3, NLRC4, or AIM1), and caspase-1. Regulation of the inflammasome is complex. However, in the case of NLRP3, reactive oxygen species (ROS), calcium signaling, mitochondrial dysfunction, and lysosome damage have all been implicated in the assembly and activation of the complex (13).

Diabetes and hyperlipidemia have been associated with excessive inflammasome activation, raising the possibility that this inflammatory complex may be relevant to diabetic complications (14, 15). It has been proposed that fatty acids mediate inflammasome activation by inhibiting AMP kinase (AMPK)-induced autophagy, leading to the accumulation of dysfunctional and ROS-generating mitochondria (10). However, in our prior studies using elicited primary macrophages, mitochondrial ROS was not increased by LPS in lipid-stressed cells (1). Instead we observed progressive lysosome dysfunction, which ultimately culminated in a cell death response. Therefore, we sought to further investigate the mechanisms of lipotoxic inflammasome activation. Our data reveal selective activation of the NLRP3 inflammasome in LPS-treated lipid stressed macrophages through lysosome- and calcineurin-dependent pathways.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Cyclosporin A and caspase-1. Regulation of the inflammasome is complex. However, in the case of NLRP3, reactive oxygen species (ROS), calcium signaling, mitochondrial dysfunction, and lysosome damage have all been implicated in the assembly and activation of the complex (13).

Diabetes and hyperlipidemia have been associated with excessive inflammasome activation, raising the possibility that this inflammatory complex may be relevant to diabetic complications (14, 15). It has been proposed that fatty acids mediate inflammasome activation by inhibiting AMP kinase (AMPK)-induced autophagy, leading to the accumulation of dysfunctional and ROS-generating mitochondria (10). However, in our prior studies using elicited primary macrophages, mitochondrial ROS was not increased by LPS in lipid-stressed cells (1). Instead we observed progressive lysosome dysfunction, which ultimately culminated in a cell death response. Therefore, we sought to further investigate the mechanisms of lipotoxic inflammasome activation. Our data reveal selective activation of the NLRP3 inflammasome in LPS-treated lipid stressed macrophages through lysosome- and calcineurin-dependent pathways.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.

EXPERIMENTAL PROCEDURES

Reagents—Triascin C, CAO74-ME, bafilomycin A, Z-YVAD, Z-VAD, and mito-TEMPO were from Enzo Life Sciences. Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) were from Tocris. Ammonium chloride, ATP, actinomycin D, Dynasore, NED-19, and 2-aminoethoxydiphenyl borate (2-APB) Z-VAD, and mito-TEMPO were from Enzo Life Sciences.
times with PBS, harvested as described above, and analyzed by flow cytometry.

Caspase-1 FLICA Flow Cytometry—After the indicated stimulations, pMACs were removed from low adherence plates as described above. The caspase-1 FLICA reagent was reconstituted per the manufacturer’s instructions and diluted in DMEM plus 10% inactivated fetal serum. Macrophages were incubated in 200 μl of staining solution for 45 min at 37°C with gentle mixing every 10 min. After the incubation, cells were washed twice in 1 ml of apoptosis wash buffer (provided with FLICA reagent) and analyzed by flow cytometry.

Statistics—Statistical analysis was performed using GraphPad Prism software. All results are expressed as means ± S.E. Groups were compared by paired Student’s t test or two-way analysis of variance as appropriate. A value of p ≤ 0.05 was considered significant.

RESULTS

SFA and LPS Activate the Lipotoxic Inflammasome—Elicited pMACs provide a tractable model system to study macrophages that enter and develop within sites of tissue injury. To evaluate the influence of lipid loading on macrophage inflammatory responses, we preincubated pMACs with 250 μM palmitate for 2 h prior to LPS challenge. This stimulation protocol led to a time- and dose-dependent release of IL-1β in a manner that required both stimuli (Fig. 1A and B). IL-1β mRNA and pro-IL-1β protein were strongly induced by LPS in the presence or absence of palmitate (Fig. 1, C and D). An LPS dose response revealed that maximal IL-1β release occurred at 50 ng/ml. The LPS response was significantly more potent than that seen with the TLR2 agonist PamCSK4, even at doses where TNFα production was similar between the two TLR stimuli (Fig. 1, E and F). We also evaluated the ability of other inflammatory ligands, including the TLR7 agonist CL075 and TNFα, to activate the lipotoxic inflammasome (Fig. 1G). LPS was the most potent inflammasome stimulus, and this occurred despite equivalent cellular activation by the TLR2 and TLR7 ligands as indicated by the TNFα mRNA response (Fig. 1H). Although IL-1β mRNA expression was slightly less in response to PamCSK4 and CL075, this was out of proportion to the marked differences in IL-1β release (Fig. 1, G and H). Of note, TNFα was a weak activator of cytokine production by pMACs (Fig. 1, G and H).

Lipotoxic Inflammasome Activation Occurs via a NLRP3 Mechanism—Consistent with inflammasome assembly, active caspase-1 was increased in palmitate-LPS-treated cells when compared with PBS or LPS stimulation (Fig. 2A). Moreover, pMACs incubated with the caspase-1-specific inhibitor Z-YVAD or the pan-caspase inhibitor Z-VAD together with necrostatin 1 (to prevent necroptosis (1)) significantly decreased IL-1β secretion (Fig. 2B). Importantly, caspase-1 inhibition did not reduce LDH release, indicating that IL-1β secretion was not a consequence of passive release from dying cells (Fig. 2C).

Inflammasomes are defined by their cryopyrin component, of which the best characterized family members are NLRP3 and NLRC4 (12). In line with prior observations (17), NLRP3 was rapidly and dramatically up-regulated in pMACs treated with LPS, irrespective of palmitate (Fig. 2D). In contrast, NLRC4 mRNA was only modestly increased at later time points after LPS stimulation, and this induction failed to occur in the presence of palmitate (Fig. 2D). To assess the functional relevance of NLRP3 in the lipotoxic inflammasome response, we stimulated NLRP3-deficient macrophages with palmitate-LPS. As seen in Fig. 2E, IL-1β release was abrogated in NLRP3 KO macrophages. In contrast, TNFα and LDH release were similar between WT and NLRP3 KO pMACs (Fig. 2, F and G). Thus, NLRP3 is required for inflammasome activation in response to lipotoxic stimuli.

Saturated Fatty Acids Are Required for Lipotoxic Inflammasome Activation—To further investigate the upstream requirements for inflammasome assembly, we evaluated other lipid and glycermic stressors. The release of IL-1β occurred in macrophages loaded with the SFAs palmitate and stearate but not the monounsaturated fatty acid oleate (Fig. 3A). IL-1β secretion was also reduced by triasacin C, an inhibitor of fatty acid esterification by acyl-CoA synthetase enzymes (Fig. 3B). Thus, IL-1β release is selectively triggered by SFAs through a mechanism that requires fatty acid activation. IL-1β secretion was similar whether macrophages were cultured in high or low glucose medium, indicating that hyperglycemic conditions are not required for the observed phenotype (Fig. 3C).

ATP can be released from dying cells and is one of the best described activators of the NLRP3 inflammasome. To determine whether ATP release was responsible for lipotoxic inflammasome activation, we utilized the compound apyrase, which rapidly degrades ATP in the media. Apyrase ablated IL-1β secretion in response to ATP but had no effect on cells stimulated with palmitate-LPS (Fig. 3D). In most models of the NLRP3 inflammasome, macrophages are pretreated with LPS (signal 1) followed by stimulation with a second “cytoplastic” stressor (signal 2). Surprisingly, when pMACs were preincubated with LPS for either 2 or 16 h followed by palmitate treatment, IL-1β secretion was markedly reduced compared with cells with simultaneous stimulation (Fig. 3E). In the same experiment, LPS-pretreated macrophages incubated with silica released substantial IL-1β. Thus, the lipotoxic inflammasome is unique among NLRP3 activators in that TLR4 must be activated concomitantly with SFA for a robust response. Together these data demonstrate that activation of the lipotoxic inflammasome by saturated fatty acids occurs via an NLRP3-dependent, ATP-independent mechanism that requires simultaneous TLR4 and lipid stress signals.

Mitochondrial ROS Primed the Lipotoxic Inflammasome—NLRP3 inflammasome activation is strongly associated with mitochondrial ROS, lysosome destabilization, and calcium signaling. However, the interplay between these elements remains poorly understood (13). We observed previously that mitochondrial ROS decreases by 16 h after palmitate-LPS treatment (1). However, ROS can also influence earlier inflammatory signaling events. To investigate the role of redox signaling, we incubated macrophages with the general antioxidants BHA and BHT, both of which reduced IL-1β with only a modest effect on TNFα release following palmitate-LPS treatment (Fig. 4, A and B). To address mitochondrial ROS specifically, macrophages were incubated with increasing concentrations of the mitochondrial targeted superoxide dismutase mimetic, mito-
TEMPO, during palmitate-LPS stimulation. Mito-TEMPO dose-dependently inhibited IL-1β/H9252 release with only a modest effect on TNFα/H9251 in the media (Fig. 4, D and E). None of the antioxidants reduced macrophage cell death as determined by LDH release (Fig. 4, C and F). It has been controversial as to whether ROS contributes to signal 1 or signal 2 in NLRP3 activation. In our system mito-TEMPO reduced IL-1β and TNFα mRNA in a manner that paralleled the secretion of these cyto-

**FIGURE 1. Palmitate and LPS activate the lipotoxic inflammasome in primary macrophages.** A, pMACs were preloaded with 250 μM palmitate (palm) or with BSA for 2 h followed by BSA or palmitate ± 50 ng/ml LPS for the indicated times, and IL-1β in the supernatant was quantified by ELISA. B, pMACs were incubated with BSA or the indicated concentrations of palmitate in combination with LPS and IL-1β release at 20 h was determined by ELISA. C, macrophages were stimulated as indicated for 4 h, and IL-1β mRNA was quantified by qRT-PCR. D, pMACs were stimulated as indicated for 16 h, and pro-IL-1β protein was assessed by Western blotting. E and F, pMACs were stimulated with the indicated doses of LPS or PamCSK4 (TLR2 ligand) with BSA or palmitate, and IL-1β (E) or TNFα (F) release was quantified at 20 h. G and H, IL-1β release at 20 h and IL-1β and TNF mRNA levels at 4 h were determined after stimulation with LPS (black bars), PamCSK4 (50 ng/ml, hatched bars), CL075 (TLR7 ligand, 500 ng/ml, gray bars), or TNFα (50 ng/ml, hatched bars) with BSA or palmitate. Bar graphs indicate the means ± S.E. for a minimum of three experiments, each performed in triplicate. *, p < 0.05 for BSA-PBS versus palmitate-LPS or LPS versus other TLR agonists.
Moreover, pro-IL-1β/H9252 protein was significantly reduced by mito-TEMPO, strongly arguing that mitochondrial ROS is a component of signal 1 and thus primes the lipotoxic inflammasome (Fig. 4).

Activation of the Lipotoxic Inflammasome Occurs via a Lyso-
some-dependent Mechanism—We have shown previously that lipid-stressed macrophages challenged with LPS develop lysosomal dysfunction, lysosomal membrane destabilization, and cathepsin release to the cytosol (1). To investigate the relationship between lysosome damage and caspase-1 activation, we utilized dual color flow cytometry employing tetracyanoboro-
diamine-dextran (lysosome label) and caspase-1 FLICA. Caspase-1 activation selectively occurred in cells where lysosome content was diminished (Fig. 5A). Cathepsin B is a lysosomal protease that has been implicated in inflammasome activation following treatment with lysosome-damaging compounds such as silica and cholesterol crystals (8, 18). The cathepsin B inhibitor CAO74 dose-dependently reduced IL-1β release from palmitate-LPS-treated pMACs, supporting a role for this pathway (Fig. 5B). To further confirm these findings, we used a chemically distinct cathepsin B inhibitor, Z-F, which produced similar results (Fig. 5C). Despite their profound inhibition of IL-1β, these compounds had only a minimal effect on TNFα release (Fig. 5D). Consistent with a role for cathepsin B in signal 2 of the inflammasome, CAO74 did not reduce pro-IL-1β/H9252 production (Fig. 5E).

Lysosomal Acidification Inhibitors Suppress Pro-IL-1β/H9252 Pro-
tduction—To further assess the role of the lysosome, we treated macrophages with the lysosomal acidification inhibitor bafilomycin A (BAF). BAF suppressed IL-1β release from macrophages in a dose-dependent fashion that correlated with its ability to neutralize lysosome pH (Fig. 6, A and B). Similar results were observed when pMACs were treated with ammonium chloride (NH4CL), a compound that neutralizes lysosome pH through an independent mechanism (Fig. 6C). TNFα release was not reduced, and in fact it was slightly increased in response to both BAF and NH4CL (Fig. 6D).
Given the results of prior studies (8, 18, 19) and our cathepsin B data, it was expected that the lysosome acidification inhibitors were acting at the level of inflammasome complex assembly (signal 2). Therefore, we were surprised to discover that BAF and NH₄Cl significantly reduced pro-IL-1β protein levels in palmitate-LPS-treated macrophages (Fig. 6E). IL-1β mRNA levels were also markedly suppressed by both BAF and NH₄Cl, whereas TNFα and NLRP3 mRNA levels were largely unaffected (Fig. 6F). To provide further evidence that lysosome acidification inhibitors and cathepsin inhibitors act at different stages of inflammasome activation, we compared the ability of CAO74 and BAF to suppress IL-1β release when the compounds were given simultaneously with LPS or delayed for 12 h. As a control, cells were treated with the caspase-1 inhibitor Z-YVAD (which should be equally inhibitory whether added early or delayed). Consistent with our predictions, the inhibitory effect of BAF was lost when it was added 12 h after stimulation, confirming its role in blocking early signaling events (Fig. 6G). In contrast, CAO74 and Z-YVAD retained their inhibitory ability at both time points (Fig. 6G). Therefore, disrupting lysosome function affects both early signaling relevant to the generation of pro-IL-1β and later events related to inflammasome complex assembly.

Impaired lysosome function also blocks autophagy, which has been implicated previously in inflammasome activation (10, 21). Therefore, we asked whether LPS stimulation of autophagy-deficient cells would be sufficient to reproduce the palmitate-LPS phenotype. To address this question, macrophages were isolated from myeloid-specific ATG5 KO mice. ATG5 KO cells treated with LPS released more IL-1β compared with WT cells; however, the magnitude of this response was small in comparison with palmitate-LPS stimulation (48 versus 2000 pg/ml, respectively) (Fig. 7A). Therefore, impaired autophagic flux does not fully explain the lipotoxic inflammasome phenotype. In fact, ATG5 KO macrophages stimulated with the combination of palmitate and LPS consistently released less IL-1β than WT littermate cells, despite similar TNFα and LDH release (Fig. 7, B and C).

Intracellular Calcium Stores Are Required for IL-1β Release in Response to Palmitate and LPS—Our data with BAF and NH₄Cl suggested that increasing lysosomal pH could disrupt signaling events that regulate IL-1β expression. Moreover, it is well known that lysosomal acidification inhibitors deplete acidic calcium stores (22). To explore a role for intracellular calcium in lipotoxic inflammasome activation, we initially used 2-APB, which blocks the release of calcium from intracellular stores (ER and lysosomes). 2-APB significantly decreased palmitate-LPS-induced IL-1β secretion, with only a modest effect on TNFα (Fig. 8, A and B). In contrast, pMACs stimulated with palmitate-LPS in calcium-free media released equivalent
amounts of IL-1β, indicating that extracellular calcium is dispensable for this phenomenon (Fig. 8C).

The bulk of intracellular calcium resides in the ER and lysosomes, both of which have channels that are inhibited by 2-APB. To more specifically address the contribution of acidic calcium stores, we utilized the compound U18666A, which rapidly depletes lysosomal calcium (23). As shown in Fig. 8, cells treated with U18666A produced significantly less IL-1β than controls (D), and this occurred in concert with reduced IL-1β mRNA (E). TNFα release was slightly augmented in cells treated with this compound (Fig. 8F). To further investigate the role of lysosomal calcium in this response, we took advantage of the compound NED-19, which selectively inhibits the NAADP-activated calcium channel that resides on the lysosome (24). NED-19-treated pMACs also secreted less IL-1β and produced less IL-1β mRNA compared with vehicle-treated cells, providing further evidence that lysosomal calcium contributes to lipotoxic inflammasome activation (Fig. 8, G–I). Together these data argue that acidic calcium stores contribute to signal 1 of inflammasome activation via effects on the production and/or stabilization of the IL-1β transcript.

**Calcineurin Inhibitors Suppress Activation of the Lipotoxic Inflammasome**—The evidence that calcium signaling influences IL-1β mRNA levels led us to investigate calcineurin, a calcium-activated phosphatase that can modulate cytokine expression. Interestingly, prior studies have demonstrated that inhibition of calcineurin by cyclosporine (CSA) reduces ATP-induced inflammasome activation. However, this was thought to occur via a mechanism that involved CSA-mediated inhibition of the mitochondrial permeability transition pore (MPTP) (25, 26). To investigate the role of calcineurin pathways in the lipotoxic inflammasome, we first assessed the effect of CSA on palmitate-LPS-induced IL-1β release. CSA dose-dependently reduced IL-1β release without significantly impacting TNFα or LDH release (Fig. 9, A–C). To address whether CSA was acting via calcineurin, we treated macrophages with FK506, a calcineurin inhibitor that has no effect on the MPTP. FK506 behaved similarly to CSA in its ability to reduce IL-1β, despite having no effect on baseline MMP as assessed by tetramethylrhodamine ethyl ester staining (TMRE, Fig. 9, D–F). To further confirm these observations, we utilized the potent calcineurin inhibitor CN585, which interacts directly with calcineurin (27).
Similar to CSA, treatment with CN585 dose-dependently reduced IL-1β secretion with a minimal effect on TNFα or LDH release (Fig. 9, G–I). These data strongly argue that calcineurin is required for full activation of the lipotoxic inflammasome.

Calcineurin Inhibitors Reduce IL-1β mRNA Stability—In light of our observations that intracellular calcium pathways regulate pro-IL-1β production, we evaluated the effect of CSA on IL-1β mRNA levels at 4, 8, and 16 h after stimulation with palmitate-LPS. Compared with vehicle, CSA had minimal effect on the early induction of IL-1β mRNA by palmitate-LPS. However, by 8 h IL-1β mRNA levels were reduced by ~50%, and this inhibitory effect persisted out to 16 h (Fig. 10A). Similar to our data obtained from the other calcium pathway inhibitors, TNFo and NLRP3 mRNA levels were not reduced at any time point (Fig. 10, B and C). Pro-IL-1β protein levels in palmitate-LPS-treated pMACs were also significantly reduced at 16 h in CSA-treated cells compared with controls (Fig. 10, D and E).

To confirm functionally that the inhibitory effects of CSA were related to early transcriptional events rather than later mitochondrial effects, we again performed a delayed inhibitor experiment in which CSA was added to cells at time 0 or delayed for 12 h, and IL-1β release was assessed. Similar to our experiments with lysosome inhibitors, the caspase-1 inhibitor Z-YVAD was used as a control. In line with our transcriptional data, macrophages treated with CSA at the time of palmitate-LPS stimulation produced dramatically less IL-1β than cells receiving CSA at 12 h (20 versus 67% of control levels, respectively) (Fig. 10F). In contrast, Z-YVAD had a similar efficacy in reducing IL-1β release, ~25% of control, whether added early or delayed (Fig. 10F). To test this concept another way, we also evaluated the effect of CSA on IL-1β release from LPS-primed macrophages treated with ATP. The rapid kinetics of NLRP3 activation by ATP (30–60 min) precludes CSA from significant impacting IL-1β transcript and/or protein levels. Consistent with its role in IL-1β mRNA regulation, CSA did not inhibit the ATP inflammasome (Fig. 10G). In fact, IL-1β release was increased in CSA-treated cells. Collectively, these findings suggest that calcineurin modulates IL-1β release via its effects on pro-IL-1β mRNA and protein.

Because the early induction of IL-1β mRNA was not affected by CSA, we hypothesized that CSA may act through reducing mRNA stability. To test this possibility, we treated pMACs with palmitate-LPS for 4 h to induce IL-1β mRNA, after which the transcriptional inhibitor actinomycin D was added in the presence or absence of CSA. IL-1β mRNA levels were subsequently assessed at 1 and 6 h. By 6 h after the addition of actinomycin D, cells treated with CSA had a 31% reduction in IL-1β mRNA compared with vehicle controls (Fig. 10H). TNFα mRNA stability was unaffected by CSA. Thus, calcineurin inhibitors prevent IL-1β release at the level of signal 1, and this occurs, at least in part, by reducing the stability of IL-1β mRNA.

**DISCUSSION**

Metabolic stress has been linked to inflammasome activation and the development of insulin resistance in the setting of obesity (10, 11). Given the central role of macrophage dysfunction in complications of metabolic disease and our previous data demonstrating markedly increased IL-1β release from lipidderrated macrophages (2), we sought to elucidate the regulatory pathways controlling lipotoxic inflammasome activation. To more closely simulate the biology of lipid-overloaded macrophages encountering an inflammatory stimulus, elicited perito-
neal macrophages were loaded with lipids prior to the addition of LPS. Using this system we observed robust IL-1β release in palmitate-enriched macrophages treated with LPS; and this was not seen with LPS or palmitate alone. IL-1β release required NLRP3 and caspase-1 activation via a mechanism that was dependent on the lysosome. Interestingly, we provide evi-
To support a novel role for lysosomal pathways in both signal 1 and signal 2 of inflammasome activation. Specifically, acidic calcium stores and calcineurin signals modulate the production of pro-IL-1β/H9252, whereas lysosomal proteases contribute to its subsequent release.

NLRP3 inflammasome activation in response to particulate stimuli such as silica, aluminum, uric acid crystals, and cholesterol crystals is thought to occur via a lysosomal damage-mediated mechanism (8, 18, 19). We had observed previously that macrophages treated with palmitate and LPS develop progressive lysosomal destabilization (1), leading us to investigate the role of this pathway in the inflammasome response. A number of our findings support a role for the lysosome in lipotoxic inflammasome activation: 1) the kinetics of IL-1β release correlated with the progression of lysosomal dysfunction (1); 2) caspase-1 activation was observed specifically within cells with lysosome impairment; 3) two chemically distinct cathepsin B inhibitors and two different lysosomal acidification inhibitors all led to profound suppression of IL-1β release without affecting TNFα/H9251; and 4) TLR agonists that activate MyD88 only (PamCSK4, TLR2; CL075, TLR7) are weak inducers of lysosome dysfunction (1) and IL-1β release.

Although autophagy is also impaired by lysosome dysfunction, this alone did not account for the observed phenotype. In fact, ATG5 KO macrophages treated with palmitate-LPS released less IL-1β compared with WT littermate controls. This surprising finding may be attributable to the role of ATG5

**FIGURE 8. Intracellular calcium stores are required for full activation of the lipotoxic inflammasome.** A and B, pMACs were stimulated as indicated in the presence of vehicle (veh, white bars) or 2-APB (100 μM, black bars) for 20 h after which IL-1β (A) and TNFα (B) release was quantified. C, cells were treated with the indicated stimuli in standard medium (std, white bars) or calcium-free DMEM (Ca free, hatched bars), and IL-1β release was assessed at 20 h by ELISA. D–F, stimulated macrophages were incubated with vehicle (white bars) versus U18666A (1 μg/ml, black bars), and IL-1β secretion (D), 8-h IL-1β mRNA (E), and TNFα release (F) were quantified. G–I, pMACs were stimulated as indicated in the presence of vehicle (white bars) or NED-19 (100 μM, black bars), and IL-1β secretion (G), 8-h IL-1β mRNA (H), and TNFα release (I) were determined. Bar graphs indicate the mean ± S.E. for a minimum of three experiments, each performed in triplicate. *, p < 0.05 for vehicle versus inhibitor. palm, palmitate. ns, not significant.
in the unconventional secretion pathway for IL-1β release (28). Of interest, our lysosome, autophagy, and ROS data are not consistent with the findings of a prior study, in which it was suggested that palmitate mediates inflammasome activation via a lysosome-independent mechanism that involves autophagy inhibition and mitochondrial ROS accumulation (10). These differences may relate to variances in the stimulation protocol (i.e., the order of LPS and palmitate addition) or intrinsic differences between bone marrow-derived and peritoneal macrophages. Further investigation will be necessary to explore these possibilities.

Lysosome damage would be predicted to deliver signal 2 of the inflammasome pathway (13), so we were surprised to discover that unlike the cathepsin inhibitors, lysosomal acidification inhibitors reduced IL-1β mRNA and protein levels. Germane to this observation, lysosomal acidification inhibitors have also been shown to deplete acidic calcium stores, raising the possibility that calcium signaling may influence IL-1β mRNA levels (22, 29). Consistent with this notion, IL-1β release was reduced significantly by 2-APB, U18666A, and NED-19, all of which disrupt the

**FIGURE 9.** Calcineurin inhibitors suppress IL-1β release during activation of the lipotoxic inflammasome. A–C, stimulated macrophages were incubated with the indicated concentrations of CSA, and IL-1β (A), TNFα (B), and LDH release (C) were quantified 20 h later. D and E, pMACs were incubated with vehicle (veh, red bars), CSA (black bars), or FK506 (FK, gray bars) during 20 h of stimulation with BSA-PBS or palmitate (palm)-LPS after which IL-1β (D) and TNFα (E) concentrations in the supernatant were determined by ELISA. F, mitochondrial membrane potential was assessed by tetramethylrhodamine ethyl ester (TMRE) staining followed by flow cytometry in pMACs incubated with vehicle (red line), CSA (black line), or FK506 (gray line) for 20 h. G–I, macrophages were stimulated in the presence of the indicated concentrations of CN585, and IL-1β (G), TNFα (H), and LDH release (I) were quantified 20 h later. Bar graphs indicate the mean ± S.E. for a minimum of three experiments, each performed in triplicate. *, p < 0.05 for vehicle versus inhibitor. ns, not significant.
release or handling of intracellular calcium stores. U18666A and NED-19 specifically modulate acidic calcium stores (23, 24). Similar to the lysosomal acidification inhibitors, these calcium-modulating compounds reduced the level of IL-1β mRNA. Together these data implicate lysosomal calcium signaling pathways in the regulation of pro-IL-1β mRNA levels; however, they do not exclude a contribution from ER calcium stores.

Calcineurin is a calcium-regulated phosphatase with known effects on inflammatory cytokine regulation. Prior studies have
shown that the calcineurin inhibitor CSA reduces IL-1β release from activated macrophages, but this has been attributed to MPTP inhibition (25, 26). In this study we found that CSA reduced IL-1β release from macrophages in response to palmitate-LPS, but this action was related to calcineurin inhibition and not blockade of the MPTP. Consistent with the other calcium-signaling inhibitors, CSA also reduced the level of IL-1β mRNA and protein (signal 1). Kinetic mRNA quantification revealed that CSA did not impact the induction of IL-1β transcription but rather reduced transcript levels over time. This action of CSA was selective for IL-1β, as this compound had no effect on TNFα or NLPR3 mRNA levels at any time point. In line with our data from the kinetic mRNA analysis, we demonstrated that calcineurin inhibition decreased IL-1β mRNA stability, accounting for at least part of the observed phenotype. Thus, calcineurin appears to be one of the important calcium-regulated proteins that modulate the expression of pro-IL-1β. Further evidence supporting the relevance of this pathway comes from a recent report demonstrating that calcineurin overexpression in cardiac myocytes also leads to enhanced IL-1β release with activation of the NLPR3 inflammasome (30).

In summary, the current study identifies the lysosome as a central player in lipotoxic inflammasome activation in primary macrophages. Early signaling events that emanate from intracellular and lysosomal calcium stores regulate the production of pro-IL-1β via a mechanism involving calcineurin and stabilization of IL-1β mRNA (signal 1). At later time points, lysosome destabilization contributes to cathepsin B-mediated activation of the NLPR3-caspase-1 complex (signal 2). Macrophage dysfunction is highly relevant to the complications of obesity and diabetes, which are frequently associated with prolonged inflammation and impaired resolution/repair. The inflammasome has been linked to this disease phenotypes (31). Our data add to the mechanistic understanding of how lipids modulate macrophage biology to affect inflammation. Future work exploring lysosome and calcineurin pathway modulators in the context of in vivo models of diabetic inflammation is of significant translational interest for the treatment of obesity/diabetic complications.

REFERENCES

1. Schilling, J. D., Machkovech, H. M., He, L., Diwan, A., and Schaffer, J. E. (2013) TLR4 activation under lipotoxic conditions leads to synergistic macrophage cell death through a TRIF-dependent pathway. J. Immunol. 190, 1285–1296
2. Schilling, J. D., Machkovech, H. M., He, L., Sidhu, R., Fujiwara, H., Weber, K., Ory, D. S., and Schaffer, J. E. (2013) Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 288, 2923–2932
3. Khanna, S., Biswas, S., Shang, Y., Collard, E., Azad, A., Kauh, C., Bhasker, V., Gordillo, G. M., Sen, C. K., and Roy, S. (2010) Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 5, e9539
4. Mirza, R., and Koh, T. J. (2011) Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine 56, 256–264
5. Kanter, J. E., Kramer, F., Barnhart, S., Averill, M. M., Vivekanandan-Giri, A., Vickery, T., Li, L. C., Becker, L., Yuan, W., Chait, A., Braun, K. R., Potter-Perigo, S., Sando, S., Wight, T. N., Pennathur, S., Serhan, C. N., Heinecke, J. W., Coleman, R. A., and Bornfeldt, K. E. (2012) Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc. Natl. Acad. Sci. U.S.A. 109, E715–E724
6. Brookheart, R. T., Michel, C. I., and Schaffer, J. E. (2009) As a matter of fat. Cell Metab. 10, 9–12
7. Henoa-Meija, J., Elinav, E., Strowig, T., and Flavell, R. A. (2012) Inflammasomes: far beyond inflammation. Nat. Immunol. 13, 321–324
8. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K. A., Rock, K. L., Moore, K. J., Wright, S. D., Hornung, V., and Lotz, E. (2010) NLPR3 inflammasomes are required for atherosclerosis and activated by cholesterol crystals. Nature 464, 1357–1361
9. Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., Kannan, H. R., Mennà, A. C., Voelkel, N. F., and Abbate, A. (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl. Acad. Sci. U.S.A. 108, 19725–19730
10. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T., Brickey, W. J., and Ting, J. P. (2011) Fatty acid-induced NLPR3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408–415
11. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., and Dixit, V. D. (2011) The NLPR3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188
12. Strowig, T., Henoa-Meija, J., Elinav, E., and Flavell, R. (2012) Inflammasomes in health and disease. Nature 481, 278–286
13. Latz, E., Xiao, T. S., and Stutz, A. (2013) Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397–411
14. De Nardo, D., and Latz, E. (2011) NLPR3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 32, 373–379
15. Lee, H. M., Kim, J. I., Kim, H. J., Shong, M., Ku, B. J., and Jo, E. K. (2013) Upregulated NLPR3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194–204
16. Listenberger, L. L., Ory, D. S., and Schaffer, J. E. (2001) Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J. Biol. Chem. 276, 14890–14895
17. Bauerfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B. G., Fitzgerald, K. A., Hornung, V., and Latz, E. (2009) Cutting edge: NF-κB-activating pattern recognition and cytokine receptors license NLPR3 inflammasome activation by regulating NLPR3 expression. J. Immunol. 183, 787–791
18. Hornung, V., Bauerfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., and Latz, E. (2008) Silica crystals and aluminum salts activate the NL3P inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847–856
19. Martinson, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241
20. Kagan, J. C., Su, T., Horng, T., Chow, A., Akira, S., and Medzhitov, R. (2008) TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9, 361–368
21. Saitoh, T., Fujita, N., Jiang, M. H., Uematsu, S., Yang, B. G., Satoh, T., Omori, H., Noda, T., Yamamoto, N., Komatsu, M., Tanaka, K., Kawai, T., Tsujimura, T., Takeuchi, O., Yoshimori, T., and Akira, S. (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264–268
22. Christensen, K. A., Myers, J. T., and Swanson, J. A. (2002) pH-dependent regulation of lysosomal calcium in macrophages. J. Cell Sci. 115, 599–607
23. Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Silence, D. J., Churchill, G. C., Schuchman, E. H., Galione, A., and Platt, E. M. (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal function. Nat. Med. 14, 1247–1255
24. Pitt, S. J., Funnell, T. M., Sitapesan, M., Venturi, E., Rietdorf, K., Ruas, M., Ganesan, A., Gosain, R., Churchill, G. C., Zuh, M. X., Partham, J., Galione, A., and Sitapesan, R. (2010) TPC2 is a novel NAADP-sensitive Ca2+ release channel, operating as a dual sensor of luminal pH and Ca2+. J. Biol. Chem. 285, 35039–35046
25. Shimada, K., Crother, T. R., Karlín, J., Dadvanor, J., Chiba, N., Chen, S., Ramanujan, V. K., Wolf, A. J., Vergnes, L., Ocius, D. M., Rentsendorj, A.,
26. Nakahira, K., Haspel, J. A., Rathinam, V. A., Lee, S. J., Dolinay, T., Lam, H. C., Englert, I. A., Rabinovitch, M., Cernadas, M., Kim, H. P., Fitzgerald, K. A., Ryter, S. W., and Choi, A. M. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222–230

27. Erdmann, F., Weiwad, M., Kilka, S., Karanik, M., Pätzel, M., Baumgrass, R., Liebscher, J., and Fischer, G. (2010) The novel calcineurin inhibitor CN585 has potent immunosuppressive properties in stimulated human T cells. J. Biol. Chem. 285, 1888–1898

28. Dupont, N., Jiang, S., Pilli, M., Ornatski, W., Bhattacharya, D., and Deretic, V. (2011) Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J. 30, 4701–4711

29. Patel, S., and Docampo, R. (2010) Acidic calcium stores open for business: expanding the potential for intracellular Ca2+ signaling. Trends Cell Biol. 20, 277–286

30. Bracey, N. A., Beck, P. L., Muruve, D. A., Hirota, S. A., Guo, J., Jabagi, H., Wright, J. R., Jr., Macdonald, J. A., Lees-Miller, J. P., Roach, D., Semeniuk, L. M., and Duff, H. J. (2013) The Nlrlp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp. Physiol. 98, 462–472

31. Mirza, R. E., Fang, M. M., Ennis, W. J., and Koh, T. J. (2013) Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes. Diabetes 62, 2579–2587